Report Highlights

U.S. Recombinant Vaccines: Market Overview

The U.S. recombinant vaccines market was valued at USD 9.8 billion in 2024 and is forecast to reach USD 16.9 billion by 2032, growing at 7.0% annually. Its structure reflects a two-stage regulatory pathway. The FDA's Center for Biologics Evaluation and Research licenses products under a Biologics License Application, while the CDC's Advisory Committee on Immunization Practices determines which products are recommended, and therefore which are reimbursed without cost-sharing.

Government has dominated demand creation rather than manufacturing. The Vaccines for Children Program, authorised under Section 1928 of the Social Security Act, purchases recombinant hepatitis B and HPV vaccines for eligible children at federally negotiated prices. Adult demand is carried by Medicare and private insurers under Section 2713 of the Affordable Care Act. Research, manufacturing and pricing remain private, led by GSK, Merck, Sanofi and Pfizer, with Novavax and Dynavax as smaller independent challengers.

Policy-Driven Growth in Recombinant Vaccines in the U.S.

The Inflation Reduction Act of 2022, Section 11401, requires Medicare Part D plans to cover ACIP-recommended adult vaccines without cost-sharing from 2023. This removed the out-of-pocket barrier for Shingrix, Arexvy and Abrysvo among beneficiaries. The mechanism is direct: once a product is on the ACIP schedule, plans absorb the full cost, and uptake rises across the 65-and-older population, the largest recombinant zoster and RSV cohort.

The Biomedical Advanced Research and Development Authority funds advanced manufacturing and procurement readiness under the Public Health Service Act. Section 317 of the same Act funds CDC immunisation grants that cover adult vaccines for uninsured adults at state level. Together these channels convert federal appropriations into state purchasing. Novavax's recombinant protein platform received USD 1.6 billion under Operation Warp Speed, establishing a government-funded production base that now supports commercial supply.

Regulatory Barriers and Compliance Costs

Biologics License Applications are reviewed by the FDA's Center for Biologics Evaluation and Research under 42 U.S.C. 262. Standard review runs roughly ten months after filing, and manufacturers must also pass pre-licence inspections under 21 CFR Parts 210, 211 and 600. Sponsors must fund large randomised trials and facility remediation, which delays entry for smaller firms. Products covered by the National Childhood Vaccine Injury Act of 1986 also carry an excise tax per dose, administered by the Internal Revenue Service and the Health Resources and Services Administration.

Price control operates mainly through procurement. CDC contracts under the Vaccines for Children Program set prices that manufacturers must accept to supply eligible children, compressing margins on paediatric recombinant products such as hepatitis B and HPV vaccines. Adult products face Medicare Part D formulary negotiation and pharmacy benefit manager rebates. Post-licensure, manufacturers must maintain pharmacovigilance and report adverse events to FDA and the Vaccine Adverse Event Reporting System, adding recurring compliance cost.

Policy-Created Opportunities in the U.S.

ACIP's 2024 recommendation of RSV prefusion F vaccines for adults aged 75 and older, and for high-risk adults aged 60 to 74, creates a defined expansion pathway. Manufacturers can pursue label extensions and pharmacy-channel uptake for these cohorts. Medicare Part D coverage makes this segment financially viable without patient co-payment barriers, opening volume that did not exist before the 2023 benefit change.

FDA's May 2025 approval of Novavax's Nuvaxovid under a full Biologics License Application, for adults aged 65 and older and high-risk individuals, creates a recombinant COVID-19 option outside mRNA platforms. Separately, ACIP's 2024 recommendation of meningococcal ABCWY combination vaccines for adolescents opens a procurement category under the Vaccines for Children Program. Bavarian Nordic's Vimkunya, approved by FDA in February 2025 for travellers, illustrates demand for virus-like particle platforms.

Regulatory and Policy Environment

The primary legislation is Section 351 of the Public Health Service Act, codified at 42 U.S.C. 262, which governs the licensing of biological products. It operates alongside the Federal Food, Drug, and Cosmetic Act and Section 2713 of the Affordable Care Act. Responsible agencies are the FDA's Center for Biologics Evaluation and Research for licensure, the CDC's ACIP for recommendations, the Centers for Medicare and Medicaid Services for Parts B and D coverage, and the HRSA for the Vaccine Injury Compensation Program. Key compliance obligations include current Good Manufacturing Practice under 21 CFR Parts 210, 211 and 600, and adverse event reporting under 21 CFR 600.80.

Regulatory change is accelerating. In June 2025 HHS replaced the ACIP membership, and in May 2025 FDA announced that new vaccines for healthy populations would require randomised placebo-controlled trials. Compared with the European Union, where the European Medicines Agency grants centralised authorisation under Regulation (EC) No 726/2004 and member states set schedules, the U.S. places recommendation and reimbursement under a single federal advisory body. That concentration gives federal policy direct control over commercial demand, a feature absent in most EU peers.

Long-Term Policy Outlook for Recombinant Vaccines in the U.S.

By 2032, the central policy question will be how recommendation authority is governed. Several state legislatures enacted laws in 2025 that reference professional society guidance alongside ACIP, creating parallel coverage pathways. Continued Inflation Reduction Act Part D redesign, including the USD 2,000 annual out-of-pocket cap introduced in 2025, will sustain adult uptake while increasing pressure on plan-level rebates for recombinant products.

Manufacturing policy will reshape supply. BARDA and the Department of Health and Human Services are expected to maintain domestic recombinant production capacity through stockpile contracts, favouring firms with U.S.-based fill-finish sites. Pricing pressure from Medicare negotiation and VFC contracts will concentrate revenue in a small number of large manufacturers, while smaller entrants depend on government procurement or licensing partnerships.

Market at a Glance

Leading Market Participants

• GSK plc
• Merck & Co.
• Pfizer Inc.
• Sanofi
• Novavax
• Dynavax Technologies
• Bavarian Nordic
• CSL Seqirus
• AstraZeneca
• Emergent BioSolutions